Stoke Therapeutics Burned $179.9 Million In Nine Months, And Its Cash Now Lasts Into Early 2028
Stoke raised $146.4 million selling stock this year, yet its cash estimate no longer mentions a U.S. launch.
Stoke Therapeutics, a late-stage company developing RNA-based medicines for severe genetic diseases, says its $358.8 million in cash and securities will fund operations "into early 2028," according to its third-quarter 10-Q filed Tuesday. The prior quarter's filing tied the runway to a potential U.S. launch of its Dravet syndrome drug in early 2028; this one drops that link.
From launch-linked to a bare date
The second-quarter 10-Q said $354.3 million, plus $65.7 million of at-the-market stock proceeds, would fund operations "through to potential U.S. commercialization of zorevunersen in early 2028." The new filing says only that cash will last into early 2028, and warns the estimate rests on assumptions that "may prove to be wrong."
The company used $179.9 million in operations over the nine months, against $76.0 million generated a year earlier. Net loss for the third quarter was $73.6 million, versus $38.3 million a year ago, and the nine-month loss was $185.3 million against net income of $51.0 million. The swing reflects the absence of $150.8 million of revenue recognized in early 2025 on the Biogen license.
Spending is climbing. Research and development reached $59.8 million in the quarter from $37.7 million, and sales, general and administrative costs reached $28.7 million from $16.0 million, with $7.9 million of that increase tied to commercial readiness. The company expects both lines to keep rising.
Stock sales keep the treasury full
Stoke sold about 4.6 million shares under its sales agreement for net proceeds of $146.4 million, according to the filing. Shares outstanding rose to 64,813,537 from 58,921,999 at the end of 2025.
An August prospectus supplement added room for up to $200.0 million more in sales; none had been sold by September 30. Unrecognized compensation cost on unvested stock options stood at $83.4 million, a further source of dilution. The company says additional equity raises would dilute existing holders.
Stoke had a market value of $1.7 billion as of Tuesday's report.
Zorevunersen timeline
Stoke's lead drug, zorevunersen, is in a global Phase 3 study for Dravet syndrome, a severe genetic epilepsy, and is partnered with Biogen outside the United States, Canada and Mexico. Enrollment is now closed, with 162 patients in the primary group. A data readout is anticipated in the third quarter of 2027, with the U.S. new drug application to be completed in the second half of 2027.
In October the company announced a successful FDA meeting on the application. It plans to assess cognition and behavior using four Vineland-3 subdomains. The company still describes preparing for a potential U.S. approval and launch in early 2028.
The company's cash runway and its readout schedule now point to the same stretch of 2027 and early 2028; the third-quarter 2027 Phase 3 data is the next dated event.
Sources
- 10-Q Filing — Stoke Therapeutics (STOK) — SEC EDGAR
- 10-Q Filing — Stoke Therapeutics (STOK), Q2 FY2026 filed 2026-08-03 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, stok-ex99_1.htm) — Stoke Therapeutics, filed 2026-10-29 — SEC EDGAR